Immunicum AB (publ) Announces Upcoming Investor Events in October and November

Press Release

22 October 2018

Immunicum AB (publ) Announces Upcoming Investor Events in October and November

Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session.   

BioStock Life Science Summit
Date: October 25, 2018
Presentation Time: 18.50 Central European Time
Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden
Registration Link:

Immunicum Investor Event – Gothenburg
Date: October 29, 2018
Presentation Time: 17.30 – 20.00 Central European Time
Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden

Immunicum Investor Event – Stockholm
Date: October 30, 2018
Presentation Time: 17.30 – 20.00 Central European Time
Venue: Ingenjörshuset Citykonferensen, Plan 1, Malmskillnadsgatan 46, 111 84 Stockholm, Sweden

RedEye Investor After Work Gothenburg
Date: November 12, 2018
Presentation Time: 18.00 Central European Time
Venue: Elite Park Avenue, Gothenburg, Sweden

RedEye Life Science Day
Date: November 21, 2018
Presentation Time: 8.40 Central European Time
Venue: Haymarket by Scandic, Stockholm, Sweden

Aktiespararna – Stora Aktiedagen
Date: November 26, 2018
Presentation Time: 8.40 – 9.10 Central European Time
Venue: Sheraton Hotel Stockholm, Tegelbacken 6, Stockholm, Sweden

Erik Penser Bank – Bolagsdag
Date: November 28, 2018
Presentation Time: 13.00 pm Central European Time
Venue: Apelbergsgatan 27, Stockholm, Sweden

To register to attend the Immunicum Investor events, please send an email to with your full name and the selected location (Gothenburg or Stockholm).

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540













About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.


Keep reading

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018